Publications
- First-line treatment for non-squamous NSCLC without driver mutations2022 | Third Faculty of Medicine
- Role of alectinib in the treatment of advanced non-small cell lung cancer2020 | Third Faculty of Medicine
- Topics of current lung cancer treatment imunoterapie, plicní karcinom, mutace, paliativní terapie in the Czech Republic to date 1. 8. 20202020 | Third Faculty of Medicine
- Alektinib v první linii léčby u nemocné s adenokarcinomem plic2020 | Third Faculty of Medicine
- Efficacy of erlotinib in subsequent lines of non-small cell lung cancer therapy2018 | Third Faculty of Medicine
- Pleural mesothelioma2023 | Third Faculty of Medicine
- ALK-positive advanced non-small cell lung cancer patient with poor performance status - case report2023 | Third Faculty of Medicine
- Amivantamab in non‐small cell lung cancer treatment2023 | Third Faculty of Medicine
- Worse Prognosis in the Symptomatic Patients With Lung Cancer - Czech Multicentric Study2022 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
Loading network view...